Stockscreener 앱 받기
72.17
2.47%
-1.83
Haemonetics Corp 주식(HAE)의 최신 뉴스
BofA Securities Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $90 - 富途牛牛
Is Haemonetics (HAE) Offering An Opportunity After Recent Share Price Weakness - Yahoo Finance
Haemonetics (NYSE:HAE) Shares Gap DownHere's What Happened - MarketBeat
Will Haemonetics (HAE) beat estimates again in its next earnings report? - MSN
Orchestra BioMed to pick up $21M through Haemonetics’ acquisition of Vivasure - MassDevice
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $93 - 富途牛牛
Haemonetics (NYSE:HAE) Stock Price Down 6.2%Here's What Happened - MarketBeat
Haemonetics Corp (HAE) Trading Down 3.8% on Jan 13 - GuruFocus
A Look At Haemonetics (HAE) Valuation After Recent Share Price Strength And Margin Expansion Targets - simplywall.st
Haemonetics price target raised to $93 from $90 at Barrington - Yahoo Finance
Haemonetics Corporation (HAE) Stock Analysis: Exploring a 10.95% Upside in the Healthcare Sector - DirectorsTalk Interviews
Haemonetics Acquires Vivasure—Could This Be Its Next Growth Engine? - Smartkarma
Galway’s Vivasure Medical acquired by Haemonetics in €185m deal - Silicon Republic
Haemonetics (HAE) Acquisition of Vivasure Boosts Orchestra BioMed's Finances - GuruFocus
EQT To Sell Stake In Irish Biz To Haemonetics In €185M Deal - Law360
Here's Why Haemonetics (HAE) is a Strong Growth Stock - Yahoo Finance
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics - The Manila Times
HAE: Barrington Research Raises Price Target, Maintains Outperfo - GuruFocus
Where Haemonetics Stands With Analysts - Benzinga
San Gabriel Valley Tribune - FinancialContent
Barrington Research Forecasts Strong Price Appreciation for Haemonetics (NYSE:HAE) Stock - MarketBeat
Ireland: Haemonetics Corporation acquires Vivasure Medical for up to €185m - Investors in Healthcare
Haemonetics acquires Ireland-based Vivasure - Medical Device Network
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics - Yahoo Finance
EQT Life Sciences Sells Vivasure Medical to Haemonetics - marketscreener.com
How Recent Moves Are Rewriting The Haemonetics (HAE) Story On Guidance And Valuation - Yahoo Finance
Haemonetics: Re-Rating Complete, Time To Cash In (NYSE:HAE) - Seeking Alpha
A Look At Haemonetics (HAE) Valuation After Recent Share Price Momentum - Yahoo Finance
Haemonetics (NYSE:HAE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Haemonetics completes €185M Vivasure acquisition - BioWorld MedTech
Haemonetics to acquire Vivasure Medical - MedTech Dive
Haemonetics acquires Vivasure Medical for EUR 100M - TipRanks
Irish medtech Vivasure sold in €185m deal to US-listed Haemonetics - Business Post
Haemonetics (NYSE:HAE) Given Buy Rating at BTIG Research - MarketBeat
BTIG Reiterates Buy Rating for Haemonetics (HAE) at $88 Price Ta - GuruFocus
Haemonetics Expands Heart Surgery Arsenal With Vivasure Acquisition - Benzinga
Irish maker of dissolving vessel-closure implant sold in €185M deal - Stock Titan
Haemonetics (HAE) Acquires Vivasure Medical for €100M - GuruFocus
Haemonetics acquires Vivasure to expand structural heart portfolio - TipRanks
Haemonetics Acquires Vivasure Medical - Nasdaq
Haemonetics Corp Acquires Vivasure Medical Limited - TradingView — Track All Markets
Haemonetics Acquires Vivasure Medical Limited - PR Newswire
Why Haemonetics Corporation stock is considered a top pick2025 Trading Recap & Fast Entry High Yield Tips - Улправда
What risks investors should watch in Haemonetics Corporation stockTreasury Yields & Comprehensive Market Scan Reports - Улправда
Why Haemonetics Corporation (HAZ) stock remains stableJuly 2025 Big Picture & Daily Profit Focused Screening - ulpravda.ru
Needham Downgrades Haemonetics(HAE.US) to Hold Rating - 富途牛牛
Plasmapheresis Machines Market Outlook 2025: Expanding - openPR.com
Haemonetics sets Feb. 5 date to share its third‑quarter results - Stock Titan
Baird Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $99 - 富途牛牛
Is Haemonetics (NYSE:HAE) Using Too Much Debt? - 富途牛牛
Haemonetics Corporation (HAE) Stock Analysis: Insights into a Promising Medical Device Leader with a 9.85% Upside - DirectorsTalk Interviews
Baird Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $99 - 富途牛牛
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term - Yahoo Finance
Investors in Haemonetics (NYSE:HAE) have unfortunately lost 35% over the last five years - Yahoo Finance
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well - simplywall.st
Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference - MarketScreener
Allspring Global Investments Holdings LLC Boosts Holdings in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (NYSE:HAE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Fort Washington Investment Advisors Inc. OH Has $34.43 Million Stock Holdings in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation $HAE Shares Sold by Boston Trust Walden Corp - MarketBeat
Haemonetics Corporation: The Vascular Closure Comeback Plan—Can VASCADE Reaccelerate Growth? - Smartkarma
0.42%
1.96%
자본화:
|
볼륨(24시간):